產(chǎn)品供應(yīng)枸櫞酸托法替尼

  • 發(fā)布日期：2024-09-10
  • 有效期限：30天
山東四環(huán)藥業(yè)股份有限公司 VIP
C16H20N6O·C6H8O7
504.497
回上一頁 在線詢盤 打印本頁
詳細(xì)信息
  • ;櫞酸托法替尼;枸櫞酸托法替布;檸檬酸托法替尼鹽;枸櫞酸托法替布枸櫞酸托法替尼;
  • 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
  • ;Tofacitinib citrate;1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-4-Ylamino)-Beta-Oxo-, (3R,4R)-, 2-Hydroxy-1,2,3-Propanetricarboxylate (1:1);1-PIPERIDINEPROPANENITRILE,4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-,(3R,4R)-,2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(1:1);Tasocitinib citrate;(3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate;Tofacitnib Citrate;
  • InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
  • 純度99%以上；
  • CAS NO：540737-29-9

免責(zé)聲明：以上所展示的信息由企業(yè)自行提供，內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布企業(yè)負(fù)責(zé)，化工網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。我們?cè)瓌t上建議您選擇化工網(wǎng)高級(jí)會(huì)員或VIP會(huì)員。